Georgios Daletos, Weaam Ebrahim, Elena Ancheeva, Mona El-Neketi, Weiguo Song, Wenhan Lin and Peter Proksch* Pages 186 - 207 ( 22 )
Background: Over the last two decades, deep-sea-derived fungi are considered to be a new source of pharmacologically active secondary metabolites for drug discovery mainly based on the underlying assumption that the uniqueness of the deep sea will give rise to equally unprecedented natural products. Indeed, up to now over 200 new metabolites have been identified from deep-sea fungi, which is in support of the statement made above. </P><P> Results: This review summarizes the new and/or bioactive compounds reported from deepsea- derived fungi in the last six years (2010 – October 2016) and critically evaluates whether the data published so far really support the notion that these fungi are a promising source of new bioactive chemical entities.
Deep-sea fungi, extremophiles, natural products, bioactive metabolites, drug discovery, bioprospecting.
Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine-University Dusseldorf, Universitatsstrasse 1, 40225 Dusseldorf, Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine-University Dusseldorf, Universitatsstrasse 1, 40225 Dusseldorf, Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine-University Dusseldorf, Universitatsstrasse 1, 40225 Dusseldorf, Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Fukang Pharma North-East of Dongwaihuan Road, Dongcheng Industrial Area, 262700 Shouguang City, State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine-University Dusseldorf, Universitatsstrasse 1, 40225 Dusseldorf